Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial

Y. Zhao, G. Chen,X. Li, J. Wu, B. Chang, S. Hu,S. Yang,Y. Liu, N. Wang,Y. Huang, L. Zhang

ANNALS OF ONCOLOGY（2022）

引用 0|浏览0

暂无评分

摘要

KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. Primary analysis of this phase II trial (data as of January 19, 2021) showed promising efficacy and well tolerated safety in advanced NSCLC pts. Herein, we present an updated analysis.

查看译文

关键词

platinum doublet chemotherapy,nsclc,treatment,two-year,first-line,open-label,multi-center

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要